KR20260046532A - 암 치료를 위한 ch5126766과 조합된 vs-6063 - Google Patents

암 치료를 위한 ch5126766과 조합된 vs-6063

Info

Publication number
KR20260046532A
KR20260046532A KR1020267009252A KR20267009252A KR20260046532A KR 20260046532 A KR20260046532 A KR 20260046532A KR 1020267009252 A KR1020267009252 A KR 1020267009252A KR 20267009252 A KR20267009252 A KR 20267009252A KR 20260046532 A KR20260046532 A KR 20260046532A
Authority
KR
South Korea
Prior art keywords
cancer
administered
pharmaceutically acceptable
inhibitor
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267009252A
Other languages
English (en)
Korean (ko)
Inventor
우다이 바네르지
Original Assignee
디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 filed Critical 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀
Publication of KR20260046532A publication Critical patent/KR20260046532A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020267009252A 2019-09-13 2020-03-12 암 치료를 위한 ch5126766과 조합된 vs-6063 Pending KR20260046532A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPPCT/EP2019/074565 2019-09-13
PCT/EP2019/074565 WO2021047783A1 (en) 2019-09-13 2019-09-13 Vs-6063 in combination with ch5126766 for the treatment of cancer
KR1020227012129A KR102945599B1 (ko) 2019-09-13 2020-03-12 암 치료를 위한 ch5126766과 조합된 vs-6063
PCT/EP2020/056642 WO2021047798A1 (en) 2019-09-13 2020-03-12 Vs-6063 in combination with ch5126766 for the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012129A Division KR102945599B1 (ko) 2019-09-13 2020-03-12 암 치료를 위한 ch5126766과 조합된 vs-6063

Publications (1)

Publication Number Publication Date
KR20260046532A true KR20260046532A (ko) 2026-04-07

Family

ID=67988988

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267009252A Pending KR20260046532A (ko) 2019-09-13 2020-03-12 암 치료를 위한 ch5126766과 조합된 vs-6063
KR1020227012129A Active KR102945599B1 (ko) 2019-09-13 2020-03-12 암 치료를 위한 ch5126766과 조합된 vs-6063

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227012129A Active KR102945599B1 (ko) 2019-09-13 2020-03-12 암 치료를 위한 ch5126766과 조합된 vs-6063

Country Status (11)

Country Link
US (4) US11517573B2 (https=)
EP (1) EP4028010B1 (https=)
JP (3) JP2022547358A (https=)
KR (2) KR20260046532A (https=)
CN (2) CN114630667B (https=)
AU (1) AU2020344829A1 (https=)
BR (1) BR112022004699A2 (https=)
CA (1) CA3152805A1 (https=)
MX (2) MX2022003063A (https=)
TW (1) TWI857024B (https=)
WO (3) WO2021047783A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547358A (ja) * 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
EP4062914A4 (en) * 2019-11-18 2024-01-17 Inxmed (Nanjing) Co., Ltd. USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION
AU2021206684B2 (en) 2020-01-10 2024-01-18 Immuneering Corporation MEK inhibitors and therapeutic uses thereof
EP4101453A4 (en) 2020-02-05 2024-05-15 Inxmed (Nanjing) Co., Ltd. COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
BR112023000675A2 (pt) * 2020-07-13 2023-04-25 Verastem Inc Terapia de combinação para tratamento de crescimento celular anormal
US20250049792A1 (en) * 2021-07-27 2025-02-13 Verastem, Inc. Combination therapy for treating abnormal cell growth
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
EP4422617A4 (en) * 2021-10-28 2025-10-15 Verastem Inc COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
CN118647382A (zh) * 2021-11-02 2024-09-13 维瑞斯特姆股份有限公司 治疗异常细胞生长的方法
WO2023138630A1 (zh) * 2022-01-21 2023-07-27 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2023147297A2 (en) * 2022-01-25 2023-08-03 Verastem, Inc. Combination therapy for treating abnormal cell growth
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN114917232A (zh) * 2022-06-27 2022-08-19 厦门骨本生物科技有限公司 Ch5126766在制备缓解或治疗动物骨关节炎的药物中的应用
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物
TW202517624A (zh) * 2023-07-03 2025-05-01 美商醫療免疫工程公司 Mek免疫腫瘤抑制劑醫藥組合物
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
CA2776944A1 (en) 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
EP2754654B1 (en) 2011-09-05 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for producing coumarin derivative
US20150071918A1 (en) 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
BR112014028376A2 (pt) 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção
WO2014059095A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Llc Combinations
EP3091981B1 (en) * 2014-01-09 2021-03-10 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
WO2015120289A1 (en) 2014-02-07 2015-08-13 Verastem, Inc. Methods and compositions for treating abnormal cell growth
US10532056B2 (en) 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
CA3074690A1 (en) * 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
RU2760006C1 (ru) 2017-11-16 2021-11-22 Дзе Инститьют оф Кансер Рисерч: Ройал Кансер Хоспитал Производное кумарина для лечения или профилактики расстройства пролиферации клеток
JP2022547358A (ja) * 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法

Also Published As

Publication number Publication date
TW202114677A (zh) 2021-04-16
BR112022004699A2 (pt) 2022-06-14
EP4028010A1 (en) 2022-07-20
JP7634351B2 (ja) 2025-02-21
CN114630667A (zh) 2022-06-14
JP2022547358A (ja) 2022-11-14
US20230277535A1 (en) 2023-09-07
KR102945599B1 (ko) 2026-03-30
WO2021047783A1 (en) 2021-03-18
JP2025072587A (ja) 2025-05-09
AU2020344829A1 (en) 2022-03-03
KR20220078606A (ko) 2022-06-10
CN114630667B (zh) 2025-05-13
US11517573B2 (en) 2022-12-06
MX2026002043A (es) 2026-04-01
US20240197731A1 (en) 2024-06-20
JP2022172480A (ja) 2022-11-17
CN120678780A (zh) 2025-09-23
US20220031698A1 (en) 2022-02-03
US12280050B2 (en) 2025-04-22
WO2021048339A1 (en) 2021-03-18
TWI857024B (zh) 2024-10-01
US20260034128A1 (en) 2026-02-05
EP4028010B1 (en) 2026-04-08
CA3152805A1 (en) 2021-03-18
MX2022003063A (es) 2022-06-14
WO2021047798A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
KR102945599B1 (ko) 암 치료를 위한 ch5126766과 조합된 vs-6063
JP2022172480A5 (https=)
EP4096671B1 (en) Combination therapy for treating abnormal cell growth
US20230330088A1 (en) Combination therapy for treating abnormal cell growth
US20230321097A1 (en) Methods and compositions for treating abnormal cell growth
KR20240041978A (ko) 비정상적 세포 성장을 치료하기 위한 조합 요법
HK40075762A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer
BR112017028519B1 (pt) Uso de defactinibe na preparação de um medicamento para tratamento de câncer

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)